Call for papers accelerates cancer information transfer - ecancermedicalscience

ecancermedicalscience aims to improve communications between sub-specialised cancer scientists and clinicians by working interactively and faster - offering authors a rapid peer review process. Submit your paper and you'll hear if it will be published within three weeks.

ecancermedicalscience (ISSN 1754-6605) is an independent online journal, publishing research articles after full peer review. All articles are published online immediately upon acceptance. The journal is published by Cancer Intelligence Ltd, Westpoint, 78 Queens Road, Clifton, Bristol, BS8 1QU.

ecancermedicalscience, founded by the European Institute of oncology, is proud to acknowledge The European CanCer Organisation as its educational and Scientific partner.

Criteria for publication
Publication of research articles by ecancermedicalscience is dependent primarily on their validity and coherence, as judged by a peer reviewer. The reviewer is asked how remarkable they consider the article to be. ecancermedicalscience is interested in publishing; innovative studies testing new hypotheses; policy research papers that challenge conventional thinking and case studies that address new and interesting ways of working.

Speed of publication
ecancermedicalscience offers fast publication whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed electronically. A web version, and accompanying PDF, will be published within a few days of acceptance.

For further information, please visit:
http://www.ecancermedicalscience.com

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...